{
  "actions": [
    {
      "acted_at": "2023-03-28",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2023-03-28",
      "action_code": "B00100",
      "references": [
        {
          "reference": "CR E267",
          "type": null
        }
      ],
      "text": "Sponsor introductory remarks on measure.",
      "type": "action"
    },
    {
      "acted_at": "2023-03-28",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2023-03-28",
      "action_code": "H11100",
      "committees": [
        "HSJU"
      ],
      "references": [],
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2023-04-07",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr1825-118",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Judiciary",
      "committee_id": "HSJU"
    }
  ],
  "congress": "118",
  "cosponsors": [
    {
      "bioguide_id": "B001302",
      "district": "5",
      "name": "Biggs, Andy",
      "original_cosponsor": true,
      "sponsored_at": "2023-03-28",
      "state": "AZ",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "C001110",
      "district": "46",
      "name": "Correa, J. Luis",
      "original_cosponsor": true,
      "sponsored_at": "2023-03-28",
      "state": "CA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "D000631",
      "district": "4",
      "name": "Dean, Madeleine",
      "original_cosponsor": true,
      "sponsored_at": "2023-03-28",
      "state": "PA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "M000194",
      "district": "1",
      "name": "Mace, Nancy",
      "original_cosponsor": true,
      "sponsored_at": "2023-03-28",
      "state": "SC",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2023-03-28",
  "number": "1825",
  "official_title": "To clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "Right to Try Clarification Act",
  "sponsor": {
    "bioguide_id": "B000574",
    "district": "3",
    "name": "Blumenauer, Earl",
    "state": "OR",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2023-03-28",
  "subjects": [
    "Health"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2023-03-28",
    "date": "2023-10-10T19:46:25Z",
    "text": "Right to Try Clarification Act\n\nThis bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).\n\nThe Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Right to Try Clarification Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Right to Try Clarification Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.",
      "type": "official"
    }
  ],
  "updated_at": "2024-07-24T15:23:10Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/118/hr/BILLSTATUS-118hr1825.xml"
}